ICU Medical, Inc. (ICUI) reported a significant profit for the third quarter, marking a successful turnaround from a net loss in the same period last year. The company’s strong performance was primarily driven by robust revenue growth in its Consumables and Infusion Systems segments, leading it to reaffirm its fiscal 2026 financial outlook with expectations of hitting the higher end of its guidance ranges.
In the third quarter, the company achieved net income of $26.8 million, or $1.07 per share, a substantial improvement compared to the net loss of $3.4 million, or $0.14 per share, recorded during the prior-year quarter.
Adjusted earnings per share rose to $2.44, up from $2.03 in the third quarter of the previous year.
Total revenue increased by 4.4% to $560.4 million, up from $537 million in the year-ago period. Additionally, gross margin showed healthy expansion, improving to 42% from 37% a year earlier.
Looking at product segments, Consumables revenue grew by 5% to $298.4 million, while Infusion Systems revenue saw an 11% increase to $192.5 million. Conversely, Vital Care revenue experienced an 11% decline, totaling $69.5 million.
With this solid momentum, ICU Medical has reaffirmed its fiscal 2026 outlook, anticipating performance toward the higher end of its previously established ranges. The company continues to project earnings per share between $2.89 and $3.29, and adjusted earnings per share in the range of $8.60 to $9.00.
Also Read
- Canada’s 2026 Federal Budget Emphasizes Sovereignty and Housing Solutions
- Stocks plunge as Dem midterm sweep fuels AI regulatory concerns
- Gunman Kills Eight in Three-Village Shooting Spree in Western Turkey Before Capture
- Trump’s Iran Standoff Faces New Political Reality as Gulf States Seek Diplomatic Off‑Ramp